|
|
Volumn 383, Issue S1, 2014, Pages S3-S5
|
|
Stratified medicines: Towards better treatment for disease
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CRIZOTINIB;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
TRASTUZUMAB;
ANTINEOPLASTIC AGENT;
EML4 ALK FUSION PROTEIN, HUMAN;
EML4-ALK FUSION PROTEIN, HUMAN;
ERBB2 PROTEIN, HUMAN;
MONOCLONAL ANTIBODY;
ONCOPROTEIN;
PROTEIN KINASE INHIBITOR;
PYRAZOLE DERIVATIVE;
PYRIDINE DERIVATIVE;
BREAST CANCER;
CLINICAL DECISION MAKING;
DIAGNOSTIC PROCEDURE;
DISEASE MANAGEMENT;
HEALTH CARE PERSONNEL;
HEALTH CARE SYSTEM;
LUNG CANCER;
MEDICINE;
NATIONAL HEALTH SERVICE;
NOTE;
PATIENT CARE;
PERSONALIZED MEDICINE;
PHARMACEUTICAL CARE;
STOMACH CANCER;
STRATIFIED MEDICINE;
ARTICLE;
BREAST TUMOR;
CONTINUING EDUCATION;
DRUG ANTAGONISM;
DRUG EFFECT;
EDUCATION;
FEMALE;
HUMAN;
INTERPERSONAL COMMUNICATION;
LUNG TUMOR;
METABOLISM;
MOLECULARLY TARGETED THERAPY;
PUBLIC HEALTH;
UNITED KINGDOM;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
COMMUNICATION;
EDUCATION, CONTINUING;
FEMALE;
GREAT BRITAIN;
HEALTH PERSONNEL;
HUMANS;
INDIVIDUALIZED MEDICINE;
LUNG NEOPLASMS;
MOLECULAR TARGETED THERAPY;
NATIONAL HEALTH PROGRAMS;
ONCOGENE PROTEINS, FUSION;
PROTEIN KINASE INHIBITORS;
PYRAZOLES;
PYRIDINES;
RECEPTOR, ERBB-2;
|
|
EID: 84898815851
PISSN: 01406736
EISSN: 1474547X
Source Type: Journal
DOI: 10.1016/S0140-6736(14)60115-X Document Type: Note |
|
Times cited : (15)
|
|
References (0)
|
